Proton pump inhibitors in chronic liver disease: accomplice or bystander?

Mak, Lung‐Yi; Fung, James

doi:10.1007/s12072-020-10033-1

Cited by 4 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, PPIs can interact with other medications commonly used in liver disease patients, emphasising the need for a careful review of the medication list and potential interactions with a specialist [97]. Lastly, the inappropriate and continuous use of PPIs in chronic liver disease patients can lead to increased healthcare costs due to frequent hospitalisations for infections, deteriorating liver function, and encephalopathy [98][99][100].…”

Section: Unveiling the Risks Of Improper And Continuous Proton Pump I...mentioning

confidence: 99%

Forgettable in the care of liver cirrhosis: the unseen culprits of progression from bad to worse

Elsabaawy,

Alhaddad

2024

View full text Add to dashboard Cite

Patients with liver cirrhosis constitute a critically ill and unique population, and their stability relies on a well-coordinated multidisciplinary team with a carefully structured plan. Overlooking any aspect of this plan can expedite disease progression, leading to severe complications. The lack of disease-specific nutritional guidance, the prevalent sedentary lifestyle among patients, and insufficient screening for hepatocellular carcinoma, oesophageal varices, sarcopaenia, minimal hepatic encephalopathy, and diabetes mellitus, along with fibrosis progression and cirrhosis decompensation, can add further complexities. Additionally, devaluing the impact of obesity in triggering liver cirrhosis can be disadvantageous. Prolonged and inappropriate use of proton pump inhibitors also poses a significant challenge with a wide range of complications. These often-unheeded aspects in the care of liver cirrhosis patients represents the unseen culprits of progression from bad to worse and warrant serious consideration.

show abstract

Section: Unveiling the Risks Of Improper And Continuous Proton Pump I...mentioning

confidence: 99%

Forgettable in the care of liver cirrhosis: the unseen culprits of progression from bad to worse

Elsabaawy,

Alhaddad

2024

View full text Add to dashboard Cite

show abstract

“…Patients taking aspirin for ≤2 years had a substantially higher risk of GI bleeding (HR, 1.73; 95% CI, 1.07–2.79) than those who did not take aspirin, but this risk decreased after 5 years of usage (HR, 0.79; 95% CI, 0.19–3.21) [ 71 ]. Prophylactic usage of a proton pump inhibitor reduces the risk of GI bleeding; however, the risk of spontaneous bacterial peritonitis, hepatic encephalopathy, and Clostridium difficile infection is a concern [ 82 ].…”

Section: Aspirin and Hcc Preventionmentioning

confidence: 99%

Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?

Goh

Sinn

2022

Clin Mol Hepatol

View full text Add to dashboard Cite

Preclinical studies highlighted potential therapeutic applications of aspirin and statins as anticancer agents based on their pleotropic effects. Epidemiologic studies suggested the role of aspirin and statins in the chemoprevention of hepatocellular carcinoma (HCC). However, observational data is prone to bias, and no prospective randomized trials are currently available to assess the risks and benefits of statin or aspirin therapy for chemoprevention of HCC. It is therefore important for clinicians and researchers to be aware of the quality of current evidence regarding this issue. In this review, we summarize currently available evidence to assist clinicians with their decision to use statin or aspirin and provide information for further clinical investigations.

show abstract